Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $60.3M | $544M | $640M | $502M | $511M | $319M |
| Revenue growth | — | 802.7% | 17.6% | -21.5% | 1.6% | -37.5% |
| Gross profit | $9.39M | $239M | $8.40M | $123M | $121M | $37.9M |
| Gross margin | 15.6% | 43.9% | 1.3% | 24.6% | 23.7% | 11.9% |
| Operating income | -$6.33M | $131M | -$2.11B | $8.96M | -$142M | -$246M |
| Operating margin | -10.5% | 24.2% | -329.5% | 1.8% | -27.8% | -77.0% |
| Net income | -$12.2M | $47.3M | -$2.15B | -$246M | -$1.44B | -$289M |
| Net margin | -20.2% | 8.7% | -335.2% | -49.1% | -281.6% | -90.5% |
| EPS (diluted) | -$0.14 | $0.20 | -$6.30 | -$0.65 | -$4.87 | -$0.88 |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$23.8M | -$56.7M | $205M | $65.1M | $42.9M | $278M |
| Capital expenditures | $0.00 | $0.00 | $384M | $16.2M | $95.0M | $729M |
| Free cash flow | -$23.8M | -$56.7M | -$179M | $49.0M | -$52.1M | -$451M |
| Share buybacks | — | — | $31.6M | $0.00 | $0.00 | — |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $8.72M | $118M | $15.9M | $50.4M | $836M | $311M |
| Total assets | $15.0K | $2.44B | $808M | $712M | $1.48B | $2.35B |
| Total liabilities | $400.00 | $1.05B | $1.22B | $1.31B | $2.42B | $3.31B |
| Shareholders' equity | $89.2M | $1.34B | -$409M | -$597M | -$943M | -$963M |
| Retained earnings | -$10.4K | -$27.4M | -$2.17B | -$2.42B | -$3.86B | -$4.15B |
| Shares (wtd avg diluted) | 158M | 233M | 341M | 380M | 256M | 318M |
Every figure is extracted from Core Scientific, Inc./tx’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.